Composite Endpoint Analysis in Clinical Trials

Composite endpoints combine multiple individual outcomes into a single measure to improve statistical power, reduce sample size and capture the multifaceted impact of interventions. They are particularly valuable in conditions with low event rates or where clinical relevance spans mortality, morbidity and patient-reported outcomes. By aggregating events such as death, hospitalisation, biomarker changes and functional measures, composite endpoints can demonstrate overall treatment effect while controlling for multiplicity. Conventional analysis typically treats each component equally, using methods for binary or time-to-event data, but this can obscure heterogeneity among components and lead to misleading interpretations if one outcome drives the composite. Recent methodological advances have introduced hierarchical and weighted approaches, such as the win ratio and net benefit frameworks, which prioritise clinically important events and allow differentiation between components. Model-based tests for heterogeneity assess consistency of treatment effects across components, while augmented binary and latent variable methods exploit continuous data to enhance precision. Adaptive designs and covariate adjustments further refine sample size calculations and inferential robustness. Global regulatory agencies and clinical consortia now emphasise transparent development of composite endpoints, highlighting unidimensional measurement theory and stakeholder-driven weighting of components. These developments aim to ensure that composite analysis balances efficiency with interpretability and aligns with patient priorities and clinical practice.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Research from all publishers

Recent work in cardiovascular trials has expanded the win ratio methodology, illustrating its application to hierarchical composites that prioritise fatal and non-fatal events, repeat episodes and quality-of-life measures. These studies provide guidance on constructing clinical hierarchies, determining sample size for win-ratio endpoints and interpreting absolute and relative benefit measures, with case studies from cardiology. Critical assessments have highlighted potential fallacies of the win ratio, such as the handling of ties, equal weighting of hierarchy levels and challenges in conveying clinical meaningfulness. A suggested framework addresses these issues by refining hierarchy definitions, incorporating time-to-event margins and ensuring transparent reporting. Broader methodological reviews stress the importance of evaluating component comparability, ensuring similar event rates and risk reductions to avoid dominance by less clinically relevant outcomes. They recommend structured decision trees for composite selection, emphasising patient-centred weighting and regulatory considerations. These analyses underscore the interplay between statistical innovation and practical trial design, calling for harmonised standards in composite endpoint construction and interpretation across therapeutic areas.

Composite Endpoint Analysis in Clinical Trials publication trend

The graph below shows the total number of articles in composite endpoint analysis in clinical trials across all publications each year (not limited to Nature Index journals).

Technical terms

Composite endpoint: A single outcome measure combining multiple individual clinical events or measurements to increase trial efficiency and capture treatment effects across diverse domains.

Win ratio: A hierarchical analysis method that compares all possible patient pairs between treatment groups according to a predefined priority of composite components, yielding a ratio of ‘wins’ to ‘losses’.

Heterogeneity test for composite outcomes: A statistical procedure to assess whether treatment effects are consistent across individual components of a composite endpoint.

Augmented binary method: An approach that retains the composite endpoint definition while utilising continuous component data to improve precision and statistical power.

References

1. The win ratio in cardiology trials: lessons learnt, new developments, and wise future use. European Heart Journal (2024).
2. Understanding the Use of Composite Endpoints in Clinical Trials. Western Journal of Emergency Medicine (2018).
3. Designing and Analyzing Clinical Trials with Composite Outcomes: Consideration of Possible Treatment Differences between the Individual Outcomes. PLOS ONE (2012).
4. Weighted analysis of composite endpoints with simultaneous inference for flexible weight constraints. Statistics in Medicine (2016).
5. Fallacies of Using the Win Ratio in Cardiovascular Trials Challenges and Solutions. JACC Basic to Translational Science (2023).
6. The Net Benefit of a treatment should take the correlation between benefits and harms into account. Journal of Clinical Epidemiology (2021).
7. Testing for heterogeneity among the components of a binary composite outcome in a clinical trial. BMC Medical Research Methodology (2010).
8. Analysis of responder-based endpoints: improving power through utilising continuous components. Trials (2020).
9. Sample size estimation using a latent variable model for mixed outcome co‐primary, multiple primary and composite endpoints. Statistics in Medicine (2022).